ZEVRA THERAPEUTICS INC. - COMMON STOCK

8,5600

26-декабря-24 16:45:00

15 мин. задержка

Акции

-0,0300

-0,35%

Сегодняшний диапазон

8,4800 - 8,6700

ISIN

N/A

Источник

NASDAQ

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

17 дек 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Announces Organizational Changes

06 дек 2024 17:00:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Conferences

26 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

21 ноя 2024 16:51:59 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

12 ноя 2024 16:05:01 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

11 ноя 2024 16:36:41 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

06 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

31 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

10 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

09 окт 2024 09:00:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

24 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

20 сен 2024 12:08:07 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

06 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Conferences

29 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

13 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

09 авг 2024 00:00:03 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Announces Proposed Public Offering of Common Stock

08 авг 2024 16:01:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

07 авг 2024 09:34:47 Источник Nasdaq GlobeNewswire
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

02 авг 2024 17:50:37 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Report Second Quarter 2024 Financial Results

30 июл 2024 08:38:30 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.